Study drug for repeat bladder tumor surgery patients
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests STM-416, given around the time you have surgery to remove recurring bladder tumors, to see if it can reduce the chance the cancer comes back. It is for people with high-risk early bladder cancer (non–muscle-invasive) who have already had standard treatment and now need another TURBT.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have had high-grade early bladder cancer (Ta or T1) without CIS, and it has come back with new papillary tumors seen on cystoscopy
- You are undergoing TURBT surgery, and you will not receive chemo into the bladder during/around the surgery
- Your cancer is considered high risk for coming back
- Your day-to-day function is good enough (ECOG 0–2)
- Your blood and organ tests are strong enough (low hemoglobin/neutrophils/platelets and poor liver/kidney results may disqualify)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether a bladder scan and score (VI-RADS from MRI) can help doctors choose the right way to do a second look surgery for non-muscle-invasive bladder cancer. The goal is to reduce the chance of needing extra (“secondary”) resections while still catching important disease early.
This study tests a new way to give a chemotherapy drug during bladder surgery to help stop the cancer from returning. It is for people with a type of bladder cancer that has not spread into the muscle.
This trial compares the need for a second surgery for people with early-stage bladder cancer. It uses a simple urine test to see if the test can help decide whether a second operation is necessary, which could save some patients from an extra procedure.
This study tests an immunotherapy drug (toripalimab) alone or followed by medication placed directly into the bladder (gemcitabine and mitomycin C) for people with high-risk bladder cancer that has not spread into the muscle wall and that has not responded to or couldn't be handled with BCG therapy. The goal is to see which approach works better.
This trial tests a combination of an immunotherapy drug (toripalimab) and a chemotherapy drug (gemcitabine) given directly into the bladder after surgery to remove high-risk bladder tumors. The goal is to reduce the chance of the cancer coming back.
This trial tests a combination of two drugs (disitamab vedotin and tislelizumab) given before a second bladder surgery (re-TURBT) for people with high-risk non-muscle invasive bladder cancer that has high HER2 levels. The goal is to see if this approach improves outcomes compared to standard care.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.